Genitourinary Cancer

Belzutifan Granted Priority Review for VHL Disease–Associated RCC

March 17, 2021

The FDA has granted priority review to the new drug application for the HIF-2α inhibitor belzutifan for the potential treatment of patients with von Hippel-Lindau–associated renal cell carcinoma that does not require immediate surgery.

Vicineum Granted Priority Review for High-Risk, BCG-Unresponsive Bladder Cancer

February 18, 2021

The FDA has accepted and granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Shorter SBRT Treatment Is Safe, Efficacious in High-Risk Prostate Cancer

January 28, 2021

A shorter course of stereotactic body radiotherapy (SBRT) has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting, according to findings from a study published in the International Journal of Radiation Oncology, Biology, Physics.